Sensus Healthcare (NASDAQ:SRTS) Director Eric Sachetta Purchases 81,575 Shares of Company Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) Director Eric Sachetta acquired 81,575 shares of the firm’s stock in a transaction on Tuesday, November 17th. The stock was purchased at an average price of $2.24 per share, for a total transaction of $182,728.00. Following the acquisition, the director directly owned 376,359 shares in the company, valued at $843,044.16. This represents a 27.67% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Eric Sachetta also recently made the following trade(s):

  • On Monday, August 31st, Eric Sachetta bought 27,304 shares of Sensus Healthcare stock. The shares were acquired at an average cost of $3.54 per share, for a total transaction of $96,656.16.
  • On Friday, August 28th, Eric Sachetta bought 37,537 shares of Sensus Healthcare stock. The shares were acquired at an average cost of $3.44 per share, with a total value of $129,127.28.
  • On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The stock was acquired at an average price of $3.18 per share, with a total value of $34,741.50.
  • On Wednesday, August 26th, Eric Sachetta purchased 9,708 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.29 per share, for a total transaction of $31,939.32.
  • On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, for a total transaction of $112,765.25.

Sensus Healthcare Stock Performance

SRTS opened at $2.36 on Friday. Sensus Healthcare, Inc. has a twelve month low of $2.14 and a twelve month high of $5.49. The firm’s 50-day moving average price is $2.91 and its 200 day moving average price is $3.39.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Sensus Healthcare had a negative net margin of 96.49% and a negative return on equity of 24.95%. The business had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $6.61 million.

Institutional Trading of Sensus Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allworth Financial LP acquired a new position in Sensus Healthcare in the third quarter valued at approximately $209,000. Cetera Investment Advisers purchased a new stake in Sensus Healthcare in the third quarter valued at $48,000. EP Wealth Advisors LLC purchased a new stake in Sensus Healthcare in the second quarter valued at $49,000. BlackRock Inc. acquired a new position in shares of Sensus Healthcare in the 2nd quarter valued at $252,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Sensus Healthcare in the 2nd quarter valued at $303,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on SRTS. Weiss Ratings lowered Sensus Healthcare from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, November 13th. Lake Street Capital cut their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.83.

Read Our Latest Stock Analysis on SRTS

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc. develops and markets medical devices for the treatment of non-melanoma skin cancer and other skin conditions. Its products use superficial radiation therapy, which delivers low-energy X-rays to targeted areas of the skin. The company’s product portfolio includes the SRT-100 platform and related systems designed for use in clinical settings. Sensus positions these technologies as non-invasive treatment options for conditions including basal and squamous cell skin cancers and keloids.

Featured Stories

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.